Rilzabrutinib is a promising treatment option for patients with chronic spontaneous urticaria who are refractory to antihistamines.

DelveInsight's B-cell Inhibitor Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable ...

Rilzabrutinib significantly alleviates itch and hives in patients with CSU unresponsive to H1-antihistamines, offering a potential new treatment option. The RILECSU trial demonstrated significant ...

Rilzabrutinib is an investigational, oral, reversible BTK inhibitor developed using Sanofi's proprietary TAILORED COVALENCY platform. This technology enables selective inhibition of BTK while ...

Immunology pipeline: New data from Sanofi’s immunology pipeline will be featured, including new analyses evaluating rilzabrutinib in moderate-to-severe asthma, and transcriptomic data in patients with ...

Sanofi has not had the success it was hoping for with its oral BTK inhibitors, acquired as part of its $3.7 billion buyout of Principia Biopharma, but can now point to a win for rilzabrutinib in ...

Add Sanofi to the list of drugmakers committing billions to bolster their operations in the United States as President Donald Trump continues to ramp up pressure on the biopharma industry.

Sanofi has scrapped its collaboration with IGM Biosciences, eliminating the biotech’s last program in the process. IGM responded by laying off 80% of its staff and closing most of its lab and ...

Morristown-based Sanofi will spend $20 billion on its U.S. operations through 2030. It also has a Massachusetts presence. Sanofi has roughly 1,900 employees in Morristown at the M Station ...

Sanofi is to buy Principia Biopharma for up ... Another of Principia’s BTK inhibitors, rilzabrutinib, is being tested in phase 3 for patients with moderate to severe pemphigus, a rare and ...

(Reuters) - Sanofi plans to invest at least $20 billion in the United States through 2030 to boost manufacturing and research, joining other drugmakers in expanding their U.S. presence in response ...